Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

762 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HIV viral load markers in clinical practice.
Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PA. Saag MS, et al. Among authors: coombs r. Nat Med. 1996 Jun;2(6):625-9. doi: 10.1038/nm0696-625. Nat Med. 1996. PMID: 8640545 Review.
A pilot study of low-dose zidovudine in human immunodeficiency virus infection.
Collier AC, Bozzette S, Coombs RW, Causey DM, Schoenfeld DA, Spector SA, Pettinelli CB, Davies G, Richman DD, Leedom JM, et al. Collier AC, et al. Among authors: coombs rw. N Engl J Med. 1990 Oct 11;323(15):1015-21. doi: 10.1056/NEJM199010113231502. N Engl J Med. 1990. PMID: 1977080 Free article. Clinical Trial.
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.
Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS, Kuritzkes DR. Japour AJ, et al. Among authors: coombs rw. J Infect Dis. 1995 May;171(5):1172-9. doi: 10.1093/infdis/171.5.1172. J Infect Dis. 1995. PMID: 7538548
Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex.
Collier AC, Coombs RW, Katzenstein D, Holodniy M, Gibson J, Mordenti J, Izu AE, Duliege AM, Ammann AJ, Merigan T, et al. Collier AC, et al. Among authors: coombs rw. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Oct 1;10(2):150-6. doi: 10.1097/00042560-199510020-00006. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7552478 Clinical Trial.
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.
D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, Richman DD. D'Aquila RT, et al. Among authors: coombs rw. Ann Intern Med. 1995 Mar 15;122(6):401-8. doi: 10.7326/0003-4819-122-6-199503150-00001. Ann Intern Med. 1995. PMID: 7856987 Clinical Trial.
Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories.
DeGruttola V, Beckett LA, Coombs RW, Arduino JM, Balfour HH Jr, Rasheed S, Hollinger FB, Fischl MA, Volberding P. DeGruttola V, et al. Among authors: coombs rw. J Infect Dis. 1994 Apr;169(4):713-21. doi: 10.1093/infdis/169.4.713. J Infect Dis. 1994. PMID: 8133085 Clinical Trial.
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.
Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, Crumpacker CS. Welles SL, et al. Among authors: coombs rw. J Infect Dis. 1996 Oct;174(4):696-703. doi: 10.1093/infdis/174.4.696. J Infect Dis. 1996. PMID: 8843205
Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.
Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, DeGruttola V, Crumpacker CS, Kahn J. Coombs RW, et al. J Infect Dis. 1996 Oct;174(4):704-12. doi: 10.1093/infdis/174.4.704. J Infect Dis. 1996. PMID: 8843206
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.
Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, Hammer SM, Hughes MD, Johnson VA, Katzenstein DA, Richman DD, Smeaton LM, Spector SA, Saag MS. Marschner IC, et al. Among authors: coombs rw. J Infect Dis. 1998 Jan;177(1):40-7. doi: 10.1086/513823. J Infect Dis. 1998. PMID: 9419168 Clinical Trial.
762 results